Loading institutional data...
Loading institutional data...
Held by 791 of 5,944 reporting institutions (98th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 41%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.” Effective rate ~3.2% on $2.2B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $1392.32 today, the market must believe free cash flow compounds 16.2%/yr for a decade (off $858M normalized FCF).
The market's 16.2% is more optimistic than its 9-yr track record.
2-stage DCF · 0.02B shares · net debt $2.2B
mean 11.4% · volatility σ 12% · implied rate exceeded in 4/9 yrs
Central path = implied 16.2%/yr growth; shaded band = ±1σ (12%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $800M buybacks = $800M returned on $849M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.03B 100.0% | $3.87B 100.0% | $3.79B 100.0% | $3.92B 100.0% | $3.72B 100.0% | $3.09B 100.0% | $3.01B 100.0% | $2.94B 100.0% | $2.73B 100.0% | $2.51B 100.0% |
| Cost of Revenue | — | — | — | — | — | — | — | — | $833.8M 30.6% | $767.8M 30.6% |
| Cost of Products | — | — | — | — | — | — | — | — | $833.8M 30.6% | $767.8M 30.6% |
| Cost of Services | — | — | — | — | — | — | — | — | $317.9M 11.7% | $304.9M 12.2% |
| Gross Profit | $2.39B 59.4% | $2.33B 60.1% | $2.24B 59.2% | $2.31B 58.9% | $2.17B 58.4% | $1.80B 58.4% | $1.74B 57.9% | $1.68B 57.4% | $1.58B 57.8% | $1.44B 57.3% |
| Research & Development | $199.4M 5.0% | $189.4M 4.9% | $185.3M 4.9% | $177.1M 4.5% | $169.8M 4.6% | $140.1M 4.5% | $143.9M 4.8% | $141.1M 4.8% | $128.3M 4.7% | $119.2M 4.8% |
| Selling, General & Admin | $998.3M 24.8% | $936.3M 24.2% | $904.1M 23.9% | $938.5M 23.9% | $944.0M 25.4% | $820.2M 26.6% | $819.2M 27.2% | $812.8M 27.7% | $794.9M 29.2% | $745.4M 29.7% |
| Interest Expense | $68.5M 1.7% | $74.6M 1.9% | $77.4M 2.0% | $55.4M 1.4% | $43.2M 1.2% | $38.6M 1.3% | $37.4M 1.2% | $34.5M 1.2% | $32.8M 1.2% | $28.0M 1.1% |
| Other Income (Expense), net | $16.8M 0.4% | $4.6M 0.1% | $4.1M 0.1% | $9.3M 0.2% | $3.1M 0.1% | $13.8M 0.4% | $6.2M 0.2% | $21.8M 0.7% | $9.9M 0.4% | $1.3M 0.1% |
| Pretax Income | $1.05B 26.1% | $1.04B 26.8% | $973.7M 25.7% | $1.07B 27.3% | $949.4M 25.5% | $748.7M 24.3% | $681.4M 22.6% | $651.9M 22.2% | $574.2M 21.1% | $504.2M 20.1% |
| Income Tax Expense | $179.7M 4.5% | $174.1M 4.5% | $184.9M 4.9% | $198.1M 5.1% | $180.4M 4.9% | $146.0M 4.7% | $120.3M 4.0% | $139.2M 4.7% | $198.3M 7.3% | $119.8M 4.8% |
| Net Income | $869.2M 21.6% | $863.1M 22.3% | $788.8M 20.8% | $872.5M 22.3% | $769.0M 20.7% | $602.7M 19.5% | $561.1M 18.6% | $512.6M 17.5% | $376.0M 13.8% | $384.4M 15.3% |
| Per Share | ||||||||||
| EPS (Basic) | $42.17 | $40.67 | $36.10 | $38.79 | $33.25 | $25.24 | $22.84 | $20.33 | $14.62 | $14.49 |
| EPS (Diluted) | $42.05 | $40.48 | $35.90 | $38.41 | $32.78 | $24.91 | $22.47 | $19.88 | $14.24 | $14.22 |
| Weighted Avg Shares (Basic) | 20.6M | 21.2M | 21.8M | 22.5M | 23.1M | 23.9M | 24.6M | 25.2M | 25.7M | 26.5M |
| Weighted Avg Shares (Diluted) | 20.7M | 21.3M | 22.0M | 22.7M | 23.5M | 24.2M | 25.0M | 25.8M | 26.4M | 27.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| MTD | $30.0B | 33.1× | — | 7.4× | 4.0% | 59.4% | 21.6% | -3677% | 40.8% | — | 791 |
Peers = companies sharing MTD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-18
Nothing notable to watch.
No material risks flagged.
Where each multiple sits in its own 14-yr range · 60th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | 57.4 | 57.9 | 58.4 | 58.4 | 58.9 | 59.2 | 60.1 | 59.4 |
| R&D | 4.8 | 4.8 | 4.5 | 4.6 | 4.5 | 4.9 | 4.9 | 5.0 |
| SG&A | 27.7 | 27.2 | 26.6 | 25.4 | 23.9 | 23.9 | 24.2 | 24.8 |
| Income Tax | 4.7 | 4.0 | 4.7 | 4.9 | 5.1 | 4.9 | 4.5 | 4.5 |
| Net Income | 17.5 | 18.6 | 19.5 | 20.7 | 22.3 | 20.8 | 22.3 | 21.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MTD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.